Urology product, experienced management, strong financial return potential in very large market ($37b-$113b) with very little competition.
Invention is treatment for Peyronie’s disease (3%-9% prevalence world adult male population). There is no dominant treatment and no dominant company in this market (one small competitor). Customers are patients with this disease reached through urologists, general practitioners and media. Hybrid Medical profitable with only 0.1% capture of only the US market at the lowest prevalence (3%).